IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, 20139 Milan, Italy.
Tumour Cell Biology Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Biomolecules. 2020 Nov 13;10(11):1548. doi: 10.3390/biom10111548.
Deregulated epidermal growth factor receptor (EGFR) signaling is a key feature in different stages of oncogenesis. One important mechanism whereby cancer cells achieve increased and uncontrolled EGFR signaling is escaping down-modulation of the receptor. Ubiquitylation of the EGFR plays a decisive role in this process, as it regulates receptor internalization, trafficking and degradation. Deubiquitinating enzymes (DUBs) may oppose the ubiquitylation process, antagonizing or even promoting receptor degradation. Here, we use qualitative and quantitative assays to measure EGFR internalization and degradation after Ubiquitin Specific Peptidase 25 (USP25) depletion. We show that, by acting at the early steps of EGFR internalization, USP25 restrains the degradation of the EGFR by assisting in the association of the E3 ubiquitin ligase c-Cbl with EGFR, thereby modulating the amplitude of ubiquitylation on the receptor. This study establishes USP25 as a negative regulator of the EGFR down-modulation process and suggests that it is a promising target for pharmacological intervention to hamper oncogenic growth signals in tumors that depend on the EGFR.
表皮生长因子受体(EGFR)信号的失调是肿瘤发生的不同阶段的一个关键特征。癌细胞实现EGFR 信号的增加和不受控制的一个重要机制是逃避受体的下调。EGFR 的泛素化在这个过程中起着决定性的作用,因为它调节受体的内化、运输和降解。去泛素化酶(DUBs)可能会对抗泛素化过程,拮抗甚至促进受体降解。在这里,我们使用定性和定量测定来测量 USP25 耗尽后 EGFR 的内化和降解。我们表明,USP25 通过作用于 EGFR 内化的早期步骤,通过协助 E3 泛素连接酶 c-Cbl 与 EGFR 的结合,从而调节受体上泛素化的幅度,来抑制 EGFR 的降解,从而限制 EGFR 的下调过程。这项研究确立了 USP25 作为 EGFR 下调过程的负调节剂,并表明它是一种有前途的药物干预靶点,以阻碍依赖 EGFR 的肿瘤中的致癌生长信号。